ai:sight > Volume 7
Volume : 07
Open Up New Possibilities
Anticipated benefits extend to an elevation in wisdom and a notable refinement in decision-making skills
editor’s note
Susmita Roy
Managing Editor
editor’s note
Taking the leap
In the dynamic realm of technological advancement, businesses tread varying paths when embracing generative AI—some with fervor, others exercising judiciousness. Particularly within the pharmaceutical sphere, renowned for its stringent regulatory framework, a measured approach prevails towards novel innovations.
Yet, there exists a compelling harmony between caution and audacity. Across industries and locales, the potential for leveraging this technology resonates universally. In this ai:sight volume, we meticulously explore these opportunities, focusing on the pharmaceutical landscape while extending insights applicable across diverse sectors.
The evolving landscape of work, a focal point of recent years, demands a recalibrated approach. Michelle King, a seasoned observer of organizational culture for over two decades, underscores the imperative of adeptly collaborating with individuals from diverse backgrounds.
Her elucidation on the significance of social acumen in navigating this transformed professional terrain offers a compelling perspective on achieving profound fulfillment amid change.
Moreover, the volume offers an extensive array of compelling interviews and perspectives. Fractal experts contribute invaluable insights spanning healthcare to quantum computing, enriching our discourse with multifaceted knowledge cutting across distinct domains.
I hope you enjoy the read.
FEATURE STORY
Why we’re prescribing AI for pharma
Generative AI is thriving, with daily reports highlighting its role in optimizing business operations across various industries, ranging from healthcare and consumer goods to financial service.
